NetworkNewsBreaks – Lexaria Bioscience Corp. (CS
Post# of 721
Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) is unwavering in its commitment to build its strategic intellectual property (“IP”) portfolio. Recently, LXRP was granted two new U.S. patents regarding cannabinoid-infused beverage compositions using its DehydraTECH ingestion technology platform. A recent article discussing the company reads, “LXRP has now filed a total of more than 50 patent applications across 10 current patent families. It is preparing applications for at least six more patents that will each form the basis for a separate patent family. It expects to file them before the end of this year, giving it management over a total of 16 patent families. The company anticipates that numerous patents will be granted within each of these families (http://nnw.fm/9BBdf). ”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer